← 프로그램 목록
Phase 1Recruiting

Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)

University of Manitoba

비교

Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)(University of Manitoba)은 Esophageal Cancer 표적 치료제로, Esophageal Cancer 영역에서 개발·상용화 중입니다. Phase 1 안전성·PK 탐색 단계입니다. OS: 12.9. 차별점: novel therapeutic approach for advancing radio-immunotherapy in brain tumors.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 13일 (1일 전)PK/독성 2026년 7월 13일 (1일 전)

Esophageal Cancer

Esophageal Cancer

Recruiting

Technology

구조모아 · StructureMoa에서 구조 검색

gene therapy

linker (3-aminophenylboronic acid)

Viral vectors, except for their safety concern, have shown high efficiency in both delivery

novel therapeutic approach for advancing radio-immunotherapy in brain tumors

Mechanism of Action

T cell activation

DNA damage accumulation, thereby further promoting apoptosis and immune activation

biomarkers like PD-L1 and TMB, alongside emerging tools such as liquid biopsy (ctDNA), are essential for pati

resistance to radioimmunotherapy

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 35건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 4 · N/A · Phase 3 · Phase 1…
  • Status: Completed · Active, not recruiting · Unknown status
  • 주요 endpoint: Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-cure (TOC) Visit · Number of Microbiologically Evaluable Patients With Clinical Response of Cure at the Test-of-cure (TOC) Visit · Number of Microbiologically Evaluable Patients by Microbiologic Response at Test-of-Cure (TOC) Visit · Minimum Inhibitory Concentration (MIC) 50 and 90 by Baseline Isolate · Inpatient Healthcare Resource Utilization on or Before Test-of-Cure - Number of Patients
  • 핵심: This research is being performed to treat patient for head and neck cancer patients who have not received prior chemothe…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)은 어떤 치료제인가요?
Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)(University of Manitoba)은 Esophageal Cancer 표적 항체로, Esophageal Cancer 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)의 임상 단계는?
Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)의 현재 단계는 Phase 1입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.